{"disease":{"id":"egfr-mutant-nsclc-and-platinum-resistant-ovarian-cancer","name":"egfr mutant nsclc and platinum resistant ovarian cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07124793","title":"A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}